ProMIS Neurosciences Inc, a clinical─stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic...
Vous n'êtes pas connecté
CHF180000 per annum: headcount AG: Join a pioneering biotech at the forefront of neurodegenerative disease research , developing next-generation therapies for Alzheimer’s, Parkinson’s, and related disorders . Using cutting-edge technologies, this company... Lausanne
ProMIS Neurosciences Inc, a clinical─stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic...
Sensorion, a pioneering clinical─stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent...
DURHAM, N.C., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene...
Rural cancer patients may miss out on cutting-edge treatments in Utah. Therapies for intellectual disorders could stall in Maryland. Red states and...
Rural cancer patients may miss out on cutting-edge treatments in Utah. Therapies for intellectual disorders could stall in Maryland. Red states and...
Alzheimer's disease (AD), a neurodegenerative disorder marked by amyloid plaque buildup and cognitive decline, remains a challenging condition to...
CHF120 - CHF125 per annum: headcount AG: Automation Engineer PCS7 – Programming Your chance to shape the future of PCS7 automation in a...
PET imaging is improved by employing edaravone to track oxidative stress, allowing for earlier detection of neurodegenerative diseases like ALS and...
When Vijay Sankaran was an MD-PhD student at Harvard Medical School in the mid-2000s, one of his first clinical encounters was with a 24-year-old...